Aelis Farma SA

Aelis Farma SA is a clinical-stage biopharmaceutical company based in Bordeaux, France, focused on discovering and developing drug candidates for central nervous system disorders. Its pipeline includes pharmacological inhibitors such as AEF0117, in Phase 2b trials for the harmful effects of excessive cannabis use; AEF0217, in Phase 1/2 trials for cognitive deficits in Down syndrome; and CB1-SSi, new molecular entities for other CB1-dependent diseases, including several orphan diseases. The company was incorporated in 2013.